Clear Cell Carcinoma of the Ovary and Uterus Clear cell carcinoma can also occur in the ovaries and uterus, where it is considered a distinct and aggressive subtype of cancer.  Ovarian Clear Cell Carcinoma (OCCC): Represents about 5-10% of ovarian cancers. It is often associated with endometriosis and tends to be diagnosed at an earlier stage than other ovarian cancers, but it has a poorer prognosis due to resistance to standard chemotherapy.  Uterine Clear Cell Carcinoma (UCCC): A rare subtype of endometrial cancer, accounting for about 1-5% of cases. UCCC is often diagnosed in postmenopausal women and is considered an aggressive cancer with a high risk of recurrence and metastasis. Diagnosis and Treatment Diagnosis of clear cell carcinoma typically involves imaging studies, such as CT scans or MRIs, followed by a biopsy to confirm the histological type. Immunohistochemistry is often used to identify markers characteristic of clear cell carcinoma. Treatment varies depending on the location and stage of the cancer. For ccRCC, surgery (partial or radical nephrectomy) is the primary treatment for localized disease, while targeted therapies and immunotherapies are used for advanced cases. For ovarian and uterine clear cell carcinomas, surgery is also a mainstay, often combined with chemotherapy and, in some cases, radiation therapy. Conclusion Clear cell carcinoma, particularly in the kidneys, is an important and often aggressive form of cancer with distinct histological and genetic features. Early detection and tailored treatment are crucial for improving patient outcomes across the different organ systems where this cancer can arise